Latest REGN news

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript

Seeking Alpha · Wed, 23 Sep 2026 14:29:52 -0400

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript

Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts

MarketBeat · Wed, 23 Sep 2026 12:04:45 -0400

Regeneron Pharmaceuticals NASDAQ: REGN executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development during a discussion with Bernstein analyst Jeffrey Walch.

Is Regeneron Stock a Bargain Below $800?

The Motley Fool · Tue, 22 Sep 2026 15:15:00 -0400

Regeneron's latest financial results were strong. The company is finding ways to overcome a recent patent cliff.

Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · Tue, 15 Sep 2026 08:49:27 -0400

Novo Nordisk continues to dominate the global diabetes and obesity care markets with its portfolio of blockbuster GLP-1 therapies. Regeneron Pharmaceuticals maintains a strong foothold in ophthalmology and immunology while expanding its pipeline through strategic collaborations.

Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum

MarketBeat · Mon, 14 Sep 2026 22:03:01 -0400

Regeneron Pharmaceuticals NASDAQ: REGN outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference.

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · Mon, 14 Sep 2026 20:31:37 -0400

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

REGN DEADLINE ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. Investors to Today's September 14, 2026 Lead Plaintiff Deadline in Securities Class Action

PRNewsWire · Mon, 14 Sep 2026 12:46:00 -0400

SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.

Market information is provided for research and visualization and is not investment advice.